Epitalon is a synthetic tetrapeptide promoted for longevity and telomere-related effects. The reviewed evidence rests largely on cell studies and publications from one Russian research group. Large, independently replicated human trials have not established an anti-aging benefit.
Research peptide
Epitalon
Epitalon is a synthetic tetrapeptide promoted for longevity and telomere-related effects. The reviewed evidence rests largely on cell studies and publications from one Russian research group. Large, independently replicated human trials have not established an anti-aging benefit.
Regulatory watch
Last reviewed Jul 12, 2026
Next review Jul 24, 2026
Evidence snapshot
Cell research: publications from the Khavinson group reported increased telomerase activity in human somatic cells.
Replication: the key telomerase and longevity claims lack broad independent confirmation.
Human outcomes: no large clinical trial has established longer life or improved healthspan.
Regulatory status: Epitalon is not FDA-approved and was scheduled for FDA advisory committee discussion in July 2026.
Research record
What the evidence record says
- Evidence grade
- Not Graded
- Regulatory status
- Epitalon regulatory status has not been fully reviewed by Peptide Report editorial team. See company profiles and regulatory watch for current status.
Evidence records
Studies, registries, reviews, and regulatory records
Evidence review pending
- Detailed evidence review for Epitalon is pending editorial assessment. Current summary reflects available public records.
Records: FDA compounding advisory committee July 2026: peptides, FDA BPC-157 compounding safety risk: immunogenicity, Peptide regulation of telomerase activity: Khavinson et al. studies of Epitalon
Evidence timeline
What changed, and when
Peptide Report last reviewed Epitalon on 2026-07-12.
Records: FDA compounding advisory committee July 2026: peptides
Direct answers
Frequently asked questions
What is Epitalon?
Epitalon is a research peptide tracked by Peptide Report. See the full profile for current editorial assessment.
Open research questions
What is still unknown
- What is the complete human evidence base for Epitalon?
- What are the long-term safety considerations for Epitalon?
Tracked claims
Epitalon is part of the July 2026 FDA peptide discussion queue.
Evidence level: Primary regulatory
Sources: FDA compounding advisory committee July 2026: peptides
How to read this: Committee review does not establish approval, safety, or clinical benefit.
Studies from a single Russian research group report that Epitalon increases telomerase activity in human cells.
Evidence level: Peer reviewed
Sources: Peptide regulation of telomerase activity: Khavinson et al. studies of Epitalon
How to read this: The telomerase claim rests on work from the Khavinson group and lacks independent Western replication. Do not present this as established anti-aging evidence.
Online longevity content promotes Epitalon as an anti-aging peptide despite the absence of large-scale human clinical trials.
Evidence level: Community discussion
Sources: Epitalon and geroprotective peptides: review of anti-aging claims, FDA BPC-157 compounding safety risk: immunogenicity
How to read this: Reviews note that geroprotective claims rest on preclinical data from limited research groups. The FDA bulk risk list applies to compounded peptide products.
Linked public records
Regulatory actions involving Epitalon
FDA advisory committee to review seven peptide-related bulk drug substances
Scheduled · Scheduled public meeting
FDA scheduled a two-day Pharmacy Compounding Advisory Committee meeting to discuss whether BPC-157, KPV, TB-500, MOTS-c, emideltide/DSIP, Semax, and Epitalon-related substances should be included on the 503A Bulks List. The committee provides advice; the meeting itself is not a final agency determination.
Compounds: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, Epitalon
Free report
Get the source-quality checklist
Use the same checklist Peptide Report uses to separate Epitalon claims, source records, supplier documentation, and media signals.
V1 collects email, role, and topic interest only. No medication, health-condition, dosing, or current-use data is collected in this form.
Formspree processes this submission for Peptide Report. Privacy notice.
Sources on this page
Each source record is linked to the claim or evidence note it supports.
July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting
FDA Pharmacy Compounding Advisory Committee meeting notice for July 23 to 24, 2026, scheduling peptide bulk substances for discussion.
23 linked pagesOpen original ·
fda-pcac-july-2026Certain bulk drug substances for use in compounding may present significant safety risks
FDA risk page lists BPC-157: compounded BPC-157 may pose immunogenicity risk and peptide-related impurity concerns for certain routes of administration.
41 linked pagesOpen original ·
fda-bulk-risk-listPeptide regulation of telomerase activity: Khavinson et al. studies of Epitalon
Studies by Khavinson and colleagues reporting that Epitalon (Ala-Glu-Asp-Gly) increases telomerase activity in human somatic cells. Research is primarily from a single Russian research group and lacks independent Western replication.
6 linked pagesOpen original ·
pubmed-epitalon-telomerase-khavinson-2003Epitalon and geroprotective peptides: review of anti-aging claims
Reviews of Epitalon and related peptides in the context of aging biology, noting that telomerase and longevity claims rest on preclinical data from limited research groups without large-scale human clinical trials.
6 linked pagesOpen original ·
pubmed-epitalon-longevity-reviewRelated compounds
BPC-157
BPC-157 is an experimental peptide with extensive animal research but very limited human evidence. A Phase 1 registry re...
Regulatory watchDSIP
Delta sleep-inducing peptide, or DSIP, was studied in small human sleep experiments during the 1970s and 1980s. Results ...
Regulatory watchKPV
KPV is a three-amino-acid fragment derived from alpha-melanocyte-stimulating hormone. Anti-inflammatory findings come fr...
Regulatory watchSemax
Semax is a synthetic ACTH-derived peptide registered as a medicine in Russia. Cognitive and attention claims rely mainly...
Regulatory watchStay informed